{"id":2446000,"date":"2019-07-04T00:00:00","date_gmt":"2019-07-04T06:00:00","guid":{"rendered":"https:\/\/www.aspentimes.com\/?p=308883"},"modified":"2019-07-04T00:00:00","modified_gmt":"2019-07-04T06:00:00","slug":"high-country-aspen-institute-tackled-cbd-psychedelics-at-ideas-festival","status":"publish","type":"post","link":"https:\/\/alwaysmountaintime.com\/kspn\/local-news\/high-country-aspen-institute-tackled-cbd-psychedelics-at-ideas-festival\/","title":{"rendered":"High Country: Aspen Institute tackled CBD, psychedelics at Ideas Festival"},"content":{"rendered":"<div class=\"swift-gallery p402_hide\" readability=\"6.7165109034268\">\n<ul id=\"imageGallery-308883-760\" class=\"gallery list-unstyled\">\n<li data-thumb=\"https:\/\/cdn.aspentimes.com\/wp-content\/uploads\/sites\/5\/2019\/07\/highcountry-atw-070419-1-150x150.jpg\" data-src=\"https:\/\/cdn.aspentimes.com\/wp-content\/uploads\/sites\/5\/2019\/07\/highcountry-atw-070419-1.jpg\" data-sub-html=\"Daniel Bayer \/ Aspen Ideas: Health |\" cbd hype or panelists to at the aspen ideas health session were matt mallory marcel and hunter class=\"h-100\" readability=\"0\">\n<div class=\"caption\" readability=\"11\">\n<p><strong>&#8220;CBD Hype or Hope?&#8221; panelists (left to right) at the Aspen Ideas Health session were Matt Laslo, Mallory Loflin, Marcel Bonn-Miller, and Hunter Land.<\/strong><br \/>Daniel Bayer \/ Aspen Ideas: Health<\/p>\n<\/div>\n<div class=\"row no-gutters h-100\">\n<div class=\"col my-auto\"><img decoding=\"async\" src=\"https:\/\/cdn.aspentimes.com\/wp-content\/uploads\/sites\/5\/2019\/07\/highcountry-atw-070419-1.jpg\" alt cbd hype or panelists to at the aspen ideas health session were matt mallory marcel and hunter><\/div>\n<\/div>\n<\/li>\n<li data-thumb=\"https:\/\/cdn.aspentimes.com\/wp-content\/uploads\/sites\/5\/2019\/07\/highcountry-atw-070419-1-1-150x150.jpg\" data-src=\"https:\/\/cdn.aspentimes.com\/wp-content\/uploads\/sites\/5\/2019\/07\/highcountry-atw-070419-1-1.jpg\" data-sub-html=\"Daniel Bayer \/ Aspen Ideas: Health |\" cbd hype or panelists at the aspen ideas health session included matt laslo and mallory class=\"h-100\" readability=\"-1.5\">\n<div class=\"caption\" readability=\"8\">\n<p><strong>&#8220;CBD Hype or Hope?&#8221; panelists at the Aspen Ideas Health session included Matt Laslo and Mallory Loflin.<\/strong><br \/>Daniel Bayer \/ Aspen Ideas: Health<\/p>\n<\/div>\n<div class=\"row no-gutters h-100\">\n<div class=\"col my-auto\"><img decoding=\"async\" src=\"https:\/\/cdn.aspentimes.com\/wp-content\/uploads\/sites\/5\/2019\/07\/highcountry-atw-070419-1-1.jpg\" alt cbd hype or panelists at the aspen ideas health session included matt laslo and mallory><\/div>\n<\/div>\n<\/li>\n<li data-thumb=\"https:\/\/cdn.aspentimes.com\/wp-content\/uploads\/sites\/5\/2019\/07\/highcountry-atw-070419-1-2-150x150.jpg\" data-src=\"https:\/\/cdn.aspentimes.com\/wp-content\/uploads\/sites\/5\/2019\/07\/highcountry-atw-070419-1-2.jpg\" data-sub-html=\"Daniel Bayer \/ Aspen Ideas: Health |\" cbd hype or panelists to at the health forum included marcel bonn-miller and hunter class=\"h-100\" readability=\"-1.5\">\n<div class=\"caption\" readability=\"8\">\n<p><strong>&#8220;CBD Hype or Hope?&#8221; panelists (left to right) at the Health forum included Marcel Bonn-Miller and Hunter Land.<\/strong><br \/>Daniel Bayer \/ Aspen Ideas: Health<\/p>\n<\/div>\n<div class=\"row no-gutters h-100\">\n<div class=\"col my-auto\"><img decoding=\"async\" src=\"https:\/\/cdn.aspentimes.com\/wp-content\/uploads\/sites\/5\/2019\/07\/highcountry-atw-070419-1-2.jpg\" alt cbd hype or panelists to at the health forum included marcel bonn-miller and hunter><\/div>\n<\/div>\n<\/li>\n<li data-thumb=\"https:\/\/cdn.aspentimes.com\/wp-content\/uploads\/sites\/5\/2019\/07\/highcountry-atw-070419-1-3-150x150.jpg\" data-src=\"https:\/\/cdn.aspentimes.com\/wp-content\/uploads\/sites\/5\/2019\/07\/highcountry-atw-070419-1-3.jpg\" data-sub-html=\"Daniel Bayer \/ Aspen Ideas: Health |\" cbd hype or panelists to at the health forum included marcel bonn-miller and hunter class=\"h-100\" readability=\"-1.5\">\n<div class=\"caption\" readability=\"8\">\n<p><strong>&#8220;CBD Hype or Hope?&#8221; panelists (left to right) at the Health forum included Marcel Bonn-Miller and Hunter Land.<\/strong><br \/>Daniel Bayer \/ Aspen Ideas: Health<\/p>\n<\/div>\n<div class=\"row no-gutters h-100\">\n<div class=\"col my-auto\"><img decoding=\"async\" src=\"https:\/\/cdn.aspentimes.com\/wp-content\/uploads\/sites\/5\/2019\/07\/highcountry-atw-070419-1-3.jpg\" alt cbd hype or panelists to at the health forum included marcel bonn-miller and hunter><\/div>\n<\/div>\n<\/li>\n<\/ul>\n<p class=\"caption-toggle\"><a href=\"https:\/\/www.aspentimes.com\/news\/marijuana\/high-country-aspen-institute-tackled-cbd-psychedelics-at-ideas-festival\/#\" class=\"show-captions\">Show Captions<\/a><a href=\"https:\/\/www.aspentimes.com\/news\/marijuana\/high-country-aspen-institute-tackled-cbd-psychedelics-at-ideas-festival\/#\" class=\"hide-captions\">Hide Captions<\/a><\/p>\n<\/div>\n<p class=\"STND-STND BodyText\">Summer festival season is in full swing in high country and on the heels of the groundbreaking debut of cannabis at the Food &amp; Wine Classic in Aspen came the 15th annual Aspen Ideas Festival, which reached a milestone of its own in presenting the two dedicated discussions on cannabidiols and psychedelics.<\/p>\n<p class=\"STND-STND BodyText\">The 10-day event is produced by the Aspen Institute, the nonprofit educational and policy studies organization based in Washington D.C., and welcomes more than 400 of the world\u2019s most prominent thought leaders spanning business, politics, media, culture and science as speakers for its 3,000 registered attendees and invited scholars.<\/p>\n<p class=\"STND-STND BodyText\">\u201cEvery year, Aspen Ideas: Health focuses on some of the hot button issues in health and medicine,\u201d says Ruth Katz, Director of the Health, Medicine and Society Program at the Aspen Institute. \u201cCBD and psychedelics are among those for 2019, as the sold-out audiences for both of these sessions clearly demonstrate. As always, in selecting our speakers, we look for the best in the business\u2014those who are recognized as leaders in the field.\u201d<\/p>\n<p class=\"STND-STND BodyText\">As part of Aspen Ideas: Health, a prequel track of programming which ran from June 20-23, organizers addressed the explosion of the cannabis plant derivative everywhere, in \u201cCBD: Hype or Hope?,\u201d which according to the official description, begged the question: \u201cThe U.S. Food and Drug Administration held its first public hearing on CBD in early June, but doesn\u2019t yet regulate the product, and concerns about mislabeling and other hazards abound. What does the science tell us about CBD? Is the $600 million market a triumph of hype or a hopeful promise?\u201d<\/p>\n<p class=\"STND-STND BodyText\">As previously reported in the <a rel=\"noreferrer noopener\" aria-label=\"(opens in a new tab)\" href=\"https:\/\/www.washingtonpost.com\/business\/2019\/06\/24\/cbd-infused-food-beverages-are-still-illegal-under-us-law-so-why-are-they-everywhere\/?noredirect=on&amp;utm_campaign=5071f4c1aa-EMAIL_CAMPAIGN_5_7_2019_14_46_COPY_01&amp;utm_medium=email&amp;utm_source=Word%20on%20the%20Tree&amp;utm_term=.036061229fc6\" target=\"_blank\">Washington Post<\/a>, on June 16 the <a href=\"https:\/\/www.fda.gov\/consumers\/consumer-updates\/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\"(opens in a new tab)\">FDA released a document<\/a> called \u201cWhat You Need to Know (And What We\u2019re Working to Find Out)\u201d that states: \u201cWe are aware that there may be some products on the market that add CBD to a food or label CBD as a dietary supplement. Under federal law, it is currently illegal to market CBD this way.\u201d Last week, a bipartisan group of lawmakers introduced a bill intended to promote federally authorized research into marijuana and its derivatives like CBD.<\/p>\n<p class=\"STND-STND BodyText\">Just as cannabis has progressed, the <a rel=\"noreferrer noopener\" aria-label=\"(opens in a new tab)\" href=\"https:\/\/www.bloomberg.com\/news\/articles\/2019-06-18\/magic-mushrooms-follow-pot-s-lead-as-decriminalization-spreads\" target=\"_blank\">psychedelic movement is following suit<\/a> in terms of how advocates are approaching decriminalization (then, legalization) for adult-use and as a regulated medicinal aid for mental health. And for an organization of the Aspen Institute\u2019s distinction to acknowledge it through a curated conversation, \u201cIs very important. It legitimizes the work we have been doing for the past 30 years,\u201d says Rick Doblin, founder and executive director of the <a href=\"https:\/\/maps.org\/\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\"(opens in a new tab)\">Multidisciplinary Association for Psychedelic Studies<\/a> (MAPS).<\/p>\n<p class=\"STND-STND BodyText\">Formed as a nonprofit in 1986, MAPS is \u201ca research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana,\u201d according to its website. Doblin prefers to refer to it as \u201can international psychedelic pharmaceutical company\u201d and employs more than 50 staff members working on designing and sponsoring studies.<\/p>\n<p class=\"STND-STND BodyText\">With a phase 3 clinical trial for MDMA-assisted psychotherapy underway and FDA approval anticipated in 2021, Doblin adds, \u201cThese days, I feel like I\u2019m in almost a perpetual state of astonishment at the way things are going, and being asked to speak this year at the Aspen Ideas Festival is just one example of approval and how rapidly our cause is moving.\u201d<\/p>\n<p class=\"STND-STND BodyText\">MAPS also recently received a $900,000 annual donation commitment for the next three years from Elizabeth Koch and counts David Bronner and Joby Pritzker as members of its Board of Directors. Doblin was one of three \u201cBad Drugs Are Looking Good\u201d Aspen Ideas panelists asked to shed a light on how, \u201cPsychedelic drugs, such as psilocybin and LSD, can trigger a schizophrenic episode, but their potential to treat addiction, control post-traumatic stress disorder, and prepare terminally ill patients for death is intriguing. Researchers are taking a fresh look at the treatment value of drugs with a reputation for danger and making some surprising discoveries.\u201d<\/p>\n<p class=\"STND-STND BodyText\">Many post-Aspen Ideas Festival questions obviously remain, but here are the top takeaways shared during each panel presentation (also available to watch in full online), to inspire future dialogue for both movements to move forward.<\/p>\n<h4><strong>CBD: Hype or Hope?<\/strong><\/h4>\n<p class=\"STND-STND BodyText\">Moderator: Matt Laslo, freelance reporter, adjunct political communications professor, Johns Hopkins University<\/p>\n<p class=\"STND-STND BodyText\">Panelists: Mallory Loflin, research scientist and principal investigator, Veterans Affairs San Diego Healthcare System; assistant professor of psychiatry, School of Medicine, University of California San Diego; Marcel Bonn-Miller, global scientific director, Canopy Growth Corporation; assistant professor of psychology, University of Pennsylvania Perelman School of Medicine; Hunter Land, associate director of cannabinoid research, Canopy Growth Corporation<\/p>\n<p class=\"STND-STND BodyText\"><strong>On drug testing:<\/strong><\/p>\n<p class=\"STND-STND BodyText\">\u201cWe tested folks that are just taking hemp extract and they\u2019re popping positive left and right at pretty decent quantities.\u201d \u2014Marcel Bonn-Miller<\/p>\n<p class=\"STND-STND BodyText\">\u201cThat depends, right. So I think some nuance around what that means, and if you\u2019re taking a whole plant extract, full-spectrum, you will probably fail a drug test. And if you\u2019re taking something where they isolate the CBD, then you probably won\u2019t.\u201d \u2014Hunter Land<\/p>\n<p class=\"STND-STND BodyText\">\u201cI think most folks don\u2019t realize that [the majority of] CBD can still contain up to 0.3 percent THC. And that, yes, especially if you\u2019re dosing chronically, that absolutely could lead to a positive drug test. And we have data.\u201d \u2014Mallory Loflin<\/p>\n<p class=\"STND-STND BodyText\"><strong>On lack of regulation:<\/strong><\/p>\n<p class=\"STND-STND BodyText\">\u201cSo not to freak everybody out \u2026 first, there are some good people and good companies on this space. But right now, the problem is the CBD market is in everything and there is actually no regulation. So, the safety of when you buy a bag of Doritos or a Hershey bar, you know that it\u2019s gone through checks and balances and has nutritional facts on it you can trust. That\u2019s not the case here. Each state is dealing with regulating this on their own and they\u2019re kind of having to create their own mini FDA\u2019s, which is crazy. You have a lot of companies that are just cranking stuff out and some don\u2019t have as much CBD as they say they have in it.\u201d \u2014Marcel Bonn-Miller<\/p>\n<p class=\"STND-STND BodyText\">\u201cI think really what we need to do is empower the consumers to say, \u2018Hey, we want clean products.\u2019 My recommendation is if you buy these products, get a legitimate lab certification. If [a CBD company] doesn\u2019t have it, but says, \u2018Oh, I promise it\u2019s fine. It\u2019s great. It\u2019s organic,\u2019 I would say that\u2019s probably inaccurate.\u201d \u2014Hunter Land<\/p>\n<p class=\"STND-STND BodyText\"><strong>On traditional medicine:<\/strong><\/p>\n<p class=\"STND-STND BodyText\">\u201cOne thing that kind of gives me hope for the future is an overwhelming majority of physicians really want education. I think a lot of physicians and practitioners are like, \u2018We don\u2019t want any recommendations without hard data to back it up,\u2019 but it means it\u2019s going to take us [researchers] a while to catch up before anything comes close to you getting a solid recommendation from your medical provider.\u201d \u2014Mallory Loflin<\/p>\n<p class=\"STND-STND BodyText\"><strong>On CBD vs. THC:<\/strong><\/p>\n<p class=\"STND-STND BodyText\">\u201cWhen talking about dosing [PTSD subjects] with CBD, we need high doses. That\u2019s very different with THC, where we would be dosing at just a few milligrams versus hundreds. A lot of our clinical data is suggesting that it looks like really high CBD oil, and very, very low THC might actually be the ticket for anxiety. But a lot of them were going to their dispensary and picking up high THC products on their own. So there\u2019s a big mismatch between what people are using and what we\u2019re actually studying.\u201d \u2014Mallory Loflin<\/p>\n<p class=\"STND-STND BodyText\">\u201cThey just have very different effects. What I like to say is, \u2018Cannabis is not cannabis is not cannabis.\u2019 When we talk about the plant, this is something that has 120 different chemical molecules in it called cannabinoids. Beyond those cannabinoids, there are terpenes, flavonoids, all sorts of different things. CBD and THC are just two of the 120 cannabinoids in the plant. Most of the work has been done on THC historically. CBD has really gotten the limelight within the past five years from a research perspective. And then there\u2019s the other 118 which we know almost nothing about.\u201d \u2014Marcel Bonn-Miller<\/p>\n<h4>Bad Drugs Are Looking Good<\/h4>\n<p class=\"STND-STND BodyText\">Moderator: John Torres, NBC News and MSNBC medical correspondent<\/p>\n<p class=\"STND-STND BodyText\">Panelists: Rick Doblin, founder and executive director, Multidisciplinary Association for Psychedelic Studies; Mallory Loflin, (see above); Dennis Charney, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, President for Academic Affairs, Mount Sinai Health System<\/p>\n<p class=\"STND-STND BodyText\"><strong>On ketamine:<\/strong><\/p>\n<p class=\"STND-STND BodyText\">\u201cThe first study showing that it was an antidepressant was based on the idea that a neurotransmitter was involved. To our surprise, somewhat, but not completely, we found that low doses produced a very rapid antidepressant effect in some patients within a few hours. And these were patients who had been depressed for many years.\u201d \u2014Dennis Charney<\/p>\n<p class=\"STND-STND BodyText\"><strong>On big pharma:<\/strong><\/p>\n<p class=\"STND-STND BodyText\">\u201cKetamine would be more effective when combined with psychotherapy instead of just being seen as a pharmacological intervention. But pharmaceutical companies don\u2019t understand anything about psychotherapy. And all of the drugs that we\u2019ve been talking about are in the public domain. And that also limits for-profit investors from getting involved, which is why we we\u2019re doing nonprofit drug development through donation.\u201d \u2014Rick Doblin<\/p>\n<p class=\"STND-STND BodyText\"><strong>On drug-assisted therapy:<\/strong><\/p>\n<p class=\"STND-STND BodyText\">\u201cIt\u2019s not about the drug. It\u2019s about the drug-therapy combination. So if people get these [substances] on their own and they shouldn\u2019t expect the same kind of results.\u201d \u2014Rick Doblin<\/p>\n<p class=\"STND-STND BodyText\"><strong>On history:<\/strong><\/p>\n<p class=\"STND-STND BodyText\">\u201cI mean, MDMA was a quietly known therapy drug from the middle of the seventies to the early eighties when it became known as the party drug, ecstasy. The sad part of this is thinking about all the unnecessary suffering that there has been when all this research was suddenly locked by the DEA. If we look at MDMA in particular, they first moved to criminalize it in 1984. That\u2019s when we had these DEA hearings, and we actually won. The judge said that MDMA should be illegal for adult-use, but it should be legal for therapeutic use. But the DEA rejected that recommendation. That was in 1986 and when I started MAPS.\u201d \u2014Rick Doblin<\/p>\n<p class=\"STND-STND BodyText\"><strong>On abuse risk:<\/strong><\/p>\n<p class=\"STND-STND BodyText\">\u201cWe\u2019re really trying to mainstream them [these drugs]. There is abuse potential and that\u2019s a big concern, but we need to educate people honestly because when we do, these exaggerated harm reduction and public education campaigns that people know are not true, then they don\u2019t know what to believe and then it\u2019s even more dangerous because they\u2019ll try things that maybe they shouldn\u2019t.\u201d \u2014Rick Doblin<\/p>\n<p class=\"STND-STND BodyText\">\u201cI think it\u2019s a really important point, too, that yes, these drugs aren\u2019t all bad, but they also aren\u2019t perfect like any medication. I think one of the biggest problems is that application is just so far out. Remember, the scientific understanding is that everybody\u2019s using them recreationally. So we kind of can\u2019t get that message out when we\u2019re in this phase of having a political battle around these substances as medication.\u201d \u2014Mallory Loflin<\/p>\n<p class=\"STND-STND BodyText\">\u201cWhen you consider the issue of abuse, people pull back and they\u2019ve pulled back too far, so now we\u2019ve got to push it [the research] forward again.\u201d \u2014Dennis Charney<\/p>\n<p class=\"STND-STND BodyText\"><strong>On psilocybin decriminalization:<\/strong><\/p>\n<p class=\"STND-STND BodyText\">\u201cThe people who are doing a lot of the work with the psilocybin, particularly at Johns Hopkins and NYU, were freaked out by that. They thought that once the science was being used for drug policy reform, they were worried that the FDA would crack down, but that\u2019s not going to happen. We [MAPS] think decriminalization is helpful because the more that the public is sort of moving in this direction, the more science will be needed. From the regulatory perspective, these efforts are helpful to us, but the thing that\u2019s unhelpful is that they make all these incredible claims and that destroys a lot of credibility.\u201d \u2014Rick Doblin<\/p>\n<p class=\"STND-STND BodyText\"><em>Katie Shapiro can be reached at <a href=\"mailto:katie@katieshapiromedia.com\">katie@katieshapiromedia.com<\/a> and followed on Twitter @bykatieshapiro.<\/em><\/p>\n<p><a href=\"https:\/\/www.aspentimes.com\/news\/marijuana\/high-country-aspen-institute-tackled-cbd-psychedelics-at-ideas-festival\/\" target=\"_blank\" rel=\"noopener noreferrer\">via:: The Aspen Times<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;CBD Hype or Hope?&#8221; panelists (left to right) at the Aspen Ideas Health session were Matt Laslo, Mallory Loflin, Marcel Bonn-Miller, and Hunter Land.Daniel Bayer \/ Aspen Ideas: Health &#8220;CBD Hype or Hope?&#8221; panelists at the Aspen Ideas Health session included Matt Laslo and Mallory Loflin.Daniel Bayer \/ Aspen Ideas: Health &#8220;CBD Hype or Hope?&#8221; [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49],"tags":[],"class_list":{"0":"post-2446000","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-local-news"},"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-20 20:03:13","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"KSPN The Valley&#039;s Quality Rock","distributor_original_site_url":"https:\/\/alwaysmountaintime.com\/kspn","push-errors":false,"_links":{"self":[{"href":"https:\/\/alwaysmountaintime.com\/kspn\/wp-json\/wp\/v2\/posts\/2446000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alwaysmountaintime.com\/kspn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alwaysmountaintime.com\/kspn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alwaysmountaintime.com\/kspn\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/alwaysmountaintime.com\/kspn\/wp-json\/wp\/v2\/comments?post=2446000"}],"version-history":[{"count":0,"href":"https:\/\/alwaysmountaintime.com\/kspn\/wp-json\/wp\/v2\/posts\/2446000\/revisions"}],"wp:attachment":[{"href":"https:\/\/alwaysmountaintime.com\/kspn\/wp-json\/wp\/v2\/media?parent=2446000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alwaysmountaintime.com\/kspn\/wp-json\/wp\/v2\/categories?post=2446000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alwaysmountaintime.com\/kspn\/wp-json\/wp\/v2\/tags?post=2446000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}